SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) — Atreca, Inc. (Atreca) BCELa clinical-stage biotechnology company focused on the development of novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced two poster presentations at the SITC 2022 Annual Meeting, to be held March 8-12 November in Boston, Massachusetts.
The details are as follows:
Title: Interim clinical update of the phase 1b study of ATRC-101 as monotherapy or in combination with pembrolizumab for selected advanced solid tumors
Poster/Abstract number: 717
Appointment time: November 10 – November 11, 9:00am – 9:00pm ET
Title: Discovery and preclinical development of a novel and differentiated antibody targeting EphA2 in multiple bispecific formats
Poster/Abstract number: 1194
Appointment time: November 10 – November 11, 9:00am – 9:00pm ET
The ATRC-101 poster presentation is a trial-in-progress update and does not contain any new clinical data. The full text of the summaries is available on the SITC website and posters will be available on the company’s website on November 10 at 9:00 am ETth.
About Atreca, Inc.
Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated from its differentiated research platform. Atreca’s platform provides access to an uncharted landscape in oncology by identifying unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies form the basis of first-in-class therapeutic candidates such as our lead product candidates ATRC-101, a monoclonal antibody targeting a novel ribonucleoprotein complex, and ATRC-301, an antibody-drug conjugate targeting a novel epitope on EphA2. A Phase 1b study evaluating ATRC-101 in multiple solid cancers is enrolling patients and ATRC-301 is in IND-enabling studies. For more information about Atreca, see www.atreca.com.
